599 related articles for article (PubMed ID: 25540023)
21. Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study.
Park YH; Seong JM; Cho S; Han HW; Kim JY; An SH; Gwak HS
J Gastroenterol; 2019 Dec; 54(12):1052-1060. PubMed ID: 31187275
[TBL] [Abstract][Full Text] [Related]
22. Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors.
Lewis PO; Litchfield JM; Tharp JL; Garcia RM; Pourmorteza M; Reddy CM
Pharmacotherapy; 2016 Sep; 36(9):986-93. PubMed ID: 27455386
[TBL] [Abstract][Full Text] [Related]
23. Acid-Suppressing Agents and Risk for Clostridium difficile Infection in Pediatric Patients.
Brown KE; Knoderer CA; Nichols KR; Crumby AS
Clin Pediatr (Phila); 2015 Oct; 54(11):1102-6. PubMed ID: 25644650
[TBL] [Abstract][Full Text] [Related]
24. Multimorbidity in elderly hospitalised patients and risk of Clostridium difficile infection: a retrospective study with the Cumulative Illness Rating Scale (CIRS).
Ticinesi A; Nouvenne A; Folesani G; Prati B; Morelli I; Guida L; Turroni F; Ventura M; Lauretani F; Maggio M; Meschi T
BMJ Open; 2015 Oct; 5(10):e009316. PubMed ID: 26503394
[TBL] [Abstract][Full Text] [Related]
25. Community-associated Clostridium difficile infection among older people in Tayside, Scotland, is associated with antibiotic exposure and care home residence: cohort study with nested case-control.
Marwick CA; Yu N; Lockhart MC; McGuigan CC; Wiuff C; Davey PG; Donnan PT
J Antimicrob Chemother; 2013 Dec; 68(12):2927-33. PubMed ID: 23825381
[TBL] [Abstract][Full Text] [Related]
26. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.
Freedberg DE; Salmasian H; Friedman C; Abrams JA
Am J Gastroenterol; 2013 Nov; 108(11):1794-801. PubMed ID: 24060760
[TBL] [Abstract][Full Text] [Related]
27. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy.
King RN; Lager SL
Pharmacotherapy; 2011 Jul; 31(7):642-8. PubMed ID: 21923450
[TBL] [Abstract][Full Text] [Related]
29. Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics.
Lewis PO; Lundberg TS; Tharp JL; Runnels CW
Ann Pharmacother; 2017 Oct; 51(10):848-854. PubMed ID: 28821215
[TBL] [Abstract][Full Text] [Related]
30. Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults.
Michal J; Henry T; Street C
Am J Health Syst Pharm; 2016 Sep; 73(17 Suppl 4):S126-32. PubMed ID: 27543598
[TBL] [Abstract][Full Text] [Related]
31. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.
Trifan A; Stanciu C; Girleanu I; Stoica OC; Singeap AM; Maxim R; Chiriac SA; Ciobica A; Boiculese L
World J Gastroenterol; 2017 Sep; 23(35):6500-6515. PubMed ID: 29085200
[TBL] [Abstract][Full Text] [Related]
32. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
Aseeri M; Schroeder T; Kramer J; Zackula R
Am J Gastroenterol; 2008 Sep; 103(9):2308-13. PubMed ID: 18702653
[TBL] [Abstract][Full Text] [Related]
33. Regional differences in Clostridium difficile infections in relation to fluoroquinolone and proton pump inhibitor use, Finland, 2008-2011.
Kanerva M; Ollgren J; Voipio T; Mentula S; Lyytikäinen O
Infect Dis (Lond); 2015 Aug; 47(8):530-5. PubMed ID: 25832317
[TBL] [Abstract][Full Text] [Related]
34. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.
Oshima T; Wu L; Li M; Fukui H; Watari J; Miwa H
J Gastroenterol; 2018 Jan; 53(1):84-94. PubMed ID: 28744822
[TBL] [Abstract][Full Text] [Related]
35. Factors Predicting Recurrence of Clostridium difficile Infection (CDI) in Hospitalized Patients: Retrospective Study of More Than 2000 Patients.
Abdelfatah M; Nayfe R; Nijim A; Enriquez K; Ali E; Watkins RR; Kandil H
J Investig Med; 2015 Jun; 63(5):747-51. PubMed ID: 25871748
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the Hospital-Acquired
Azab M; Doo L; Doo DH; Elmofti Y; Ahmed M; Cadavona JJ; Liu XB; Shafi A; Joo MK; Yoo JW
Gut Liver; 2017 Nov; 11(6):781-788. PubMed ID: 28506028
[TBL] [Abstract][Full Text] [Related]
37. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection.
Cao F; Chen CX; Wang M; Liao HR; Wang MX; Hua SZ; Huang B; Xiong Y; Zhang JY; Xu YL
J Hosp Infect; 2018 Jan; 98(1):4-13. PubMed ID: 28842261
[TBL] [Abstract][Full Text] [Related]
38. Association of Clostridium difficile infections with acid suppression medications in children.
Nylund CM; Eide M; Gorman GH
J Pediatr; 2014 Nov; 165(5):979-84.e1. PubMed ID: 25112692
[TBL] [Abstract][Full Text] [Related]
39. Length of stay and mortality due to Clostridium difficile infection acquired in the intensive care unit.
Dodek PM; Norena M; Ayas NT; Romney M; Wong H
J Crit Care; 2013 Aug; 28(4):335-40. PubMed ID: 23337482
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.
Chitnis AS; Holzbauer SM; Belflower RM; Winston LG; Bamberg WM; Lyons C; Farley MM; Dumyati GK; Wilson LE; Beldavs ZG; Dunn JR; Gould LH; MacCannell DR; Gerding DN; McDonald LC; Lessa FC
JAMA Intern Med; 2013 Jul; 173(14):1359-67. PubMed ID: 23780507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
